Loading patent…
AssigneeTargED Biopharmaceuticals B.V.
InventorsCoen Maas, Steven De Maat
Estimating the term…
The present invention provides fusion proteins for targeted delivery of plasminogen activators to platelet-VWF complexes, or alternatively to the site where these are located, in a fibrin-independent manner. The fusion protein of the invention are for use in methods for the prevention or treatment of diseases or conditions associated with such platelet-VWF complexes, which may cause microvascular thrombosis in diseases such as e.g. thrombotic thrombocytopenic purpura. Preferred targeting agents for incorporation into the fusion proteins are e.g. nanobodies against VWF or platelets. Preferred plasminogen activators for use in the fusion proteins comprise the protease domains of uPA or tPA. The invention further pertains to nucleic acid molecule encoding the fusion proteins of the invention, e.g. a gene therapy vector, and to pharmaceutical compositions comprising the fusion proteins of the invention or such gene therapy vectors.
A fusion protein comprising a plasminogen activator and a targeting agent for targeting the plasminogen activator to a site of a thrombus comprising Von Willebrand factor (VWF), wherein the targeting agent is a heavy chain antibody (VHH) that comprises an amino acid sequence at least 90% identical to amino acids 55-178 of SEQ ID NO:7, and wherein the plasminogen activator comprises the protease domain of urokinase plasminogen activator.
Dependencies are inferred from the claim text.